Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Increased by Boothbay Fund Management LLC

Boothbay Fund Management LLC raised its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 7.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 650,023 shares of the company’s stock after buying an additional 44,067 shares during the period. Boothbay Fund Management LLC owned about 1.31% of Mineralys Therapeutics worth $8,002,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Mineralys Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock valued at $130,000 after acquiring an additional 989 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Mineralys Therapeutics during the fourth quarter valued at $145,000. EntryPoint Capital LLC purchased a new stake in shares of Mineralys Therapeutics during the fourth quarter valued at $154,000. AlphaQuest LLC boosted its position in shares of Mineralys Therapeutics by 2,637.8% in the 4th quarter. AlphaQuest LLC now owns 15,222 shares of the company’s stock valued at $187,000 after purchasing an additional 14,666 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in Mineralys Therapeutics in the 4th quarter worth about $202,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Mineralys Therapeutics Price Performance

NASDAQ:MLYS opened at $13.34 on Friday. The stock has a market cap of $865.45 million, a PE ratio of -3.66 and a beta of -0.39. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $18.38. The stock’s 50-day moving average is $12.92 and its two-hundred day moving average is $12.36.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. On average, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Insider Activity

In other Mineralys Therapeutics news, major shareholder Samsara Biocapital Gp, Llc bought 600,000 shares of Mineralys Therapeutics stock in a transaction on Thursday, March 13th. The stock was purchased at an average cost of $13.50 per share, for a total transaction of $8,100,000.00. Following the completion of the purchase, the insider now directly owns 5,674,916 shares of the company’s stock, valued at $76,611,366. The trade was a 11.82 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Malcom Rodman sold 11,366 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $14.53, for a total transaction of $165,147.98. Following the completion of the sale, the insider now directly owns 111,686 shares of the company’s stock, valued at $1,622,797.58. This represents a 9.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 93,213 shares of company stock worth $1,360,567 in the last ninety days. Corporate insiders own 33.24% of the company’s stock.

Wall Street Analysts Forecast Growth

MLYS has been the subject of a number of analyst reports. HC Wainwright upped their price objective on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, April 2nd. Guggenheim reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th. Finally, The Goldman Sachs Group lowered their price objective on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.